Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 968-978

  Ahn, Eun Hyun ^a,b   Mercado, Gabriela E ^a,d   Laé, Marick ^c,e   Ladanyi, Marc ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^e INSTITUT CURIE   (France)

Author keywords

Gene expression; Microarray; PAX3 FOXO1; Rabdomyosarcoma

Indexed keywords

TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

APOPTOSIS; ARTICLE; CELL DEATH; CELL MATURATION; CONTROLLED STUDY; DAPK1 GENE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TARGETING; GREM1 GENE; HEY1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; MYOD1 GENE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; DEATH-ASSOCIATED PROTEIN KINASES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOD PROTEIN; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; RHABDOMYOSARCOMA, ALVEOLAR; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84878175019     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2513     Document Type: Article

References (40)

1. Linardic CM: PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett 270: 10-18, 2008.
2. Sorensen PH, Lynch JC, Qualman SJ, et al: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 20: 2672-2679, 2002. (Pubitemid 34575640)
3. Stevens MC: Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 6: 77-84, 2005.
4. Scrable HJ, Witte DP, Lampkin BC and Cavenee WK: Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 329: 645-647, 1987. (Pubitemid 17140118)
5. Visser M, Sijmons C, Bras J, et al: Allelotype of pediatric rhabdomyosarcoma. Oncogene 15: 1309-1314, 1997. (Pubitemid 27429747)
6. Davis RJ and Barr FG: Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA 94: 8047-8051, 1997. (Pubitemid 27343774)
7. Du S, Lawrence EJ, Strzelecki D, Rajput P, Xia SJ, Gottesman DM and Barr FG: Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma. Int J Cancer 115: 85-92, 2005. (Pubitemid 40559671)
8. Kelly KM, Womer RB, Sorensen PHB, Xiong QB and Barr FG: Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 15: 1831-1836, 1997. (Pubitemid 27209511)
9. Anderson J, Gordon T, McManus A, et al: Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 85: 831-835, 2001. (Pubitemid 33010549)
10. Khan J, Bittner ML, Saal LH, et al: cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 96: 13264-13269, 1999.
11. Wachtel M, Dettling M, Koscielniak E, et al: Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;q23) translocation fusing PAX3 to NCOA1. Cancer Res 64: 5539-5545, 2004. (Pubitemid 39095545)
12. Wachtel M, Runge T, Leuschner I, et al: Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24: 816-822, 2006. (Pubitemid 46622049)
13. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ and Anderson MJ: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcoma. Cancer Res 66: 6936-6946, 2006. (Pubitemid 44197668)
14. De Pittà C, Tombolan L, Albiero G, et al: Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer 118: 2772-2781, 2006. (Pubitemid 43673356)
15. Laé M, Ahn EH, Mercado GE, et al: Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FOXO1 fusion-negative embryonal rhabdomyosarcomas. J Pathol 212: 143-151, 2007. (Pubitemid 46852092)
16. Mercado GE, Xia SJ, Zhang C, et al: Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 47: 510-520, 2008. (Pubitemid 351657186)
17. Barr FG, Smith LM, Lynch JC, Strzelecki D, Parham DM, Qualman SJ and Breitfeld PP: Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J Mol Diagn 8: 202-208, 2006. (Pubitemid 43811243)
18. Bennicelli JL, Edwards RH and Barr FG: Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA 93: 5455-5459, 1996. (Pubitemid 26159471)
19. Tomescu O, Xia SJ, Strezlecki D, Bennicelli JL, Ginsberg J, Pawel B and Barr FG: Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab Invest 84: 1060-1070, 2004. (Pubitemid 39025040)
20. Xia SJ and Barr FG: Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene 23: 6864-6871, 2004. (Pubitemid 39279987)
21. Xia SJ, Rajput P, Strzelecki DM and Barr FG: Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein. Lab Invest 87: 318-325, 2007. (Pubitemid 46474564)
22. Littlewood TD, Hancock DC, Danielian PS, Parker MG and Evan GI: A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690, 1995.
23. Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121, 2001. (Pubitemid 32397092)
24. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
25. Ahn EH and Schroeder JJ: Sphinganine causes early activation of JNK and p38 MAPK and inhibition of AKT in HT-29 human colon cancer cells. Anticancer Res 26: 121-127, 2006. (Pubitemid 43206068)
26. Tonin PN, Scrable H, Shimada H and Cavenee WK: Musclespecific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 51: 5100-5106, 1991.
27. Tapscott SJ, Thayer MJ and Weintraub H: Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 259: 1450-1453, 1993. (Pubitemid 23101380)
28. Ren YX, Finckenstein FG, Abdueva DA, et al: Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 68: 6587-6597, 2008.
29. Graf Finckenstein F, Shahbazian V, Davicioni E, Ren YX and Anderson MJ: PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene 27: 2004-2014, 2008. (Pubitemid 351442734)
30. Sun J, Kamei CN, Layne MD, Jain MK, Liao JK, Lee ME and Chin MT: Regulation of myogenic terminal differentiation by the hairy-related transcription factor CHF2. J Biol Chem 276: 18591-18596, 2001.
31. Epstein JA, Lam P, Jepeal L, Maas RL and Shapiro DN: Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270: 11719-11722, 1995.
32. Ebauer M, Wachtel M, Niggli FK and Schäfer BW: Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 26: 7267-7281, 2007. (Pubitemid 350085317)
33. Kikuchi K, Tsuchiya K, Otabe O, et al: Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 365: 568-574, 2008. (Pubitemid 350181685)
34. Collins MH, Zhao H, Womer RB and Barr FG: Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol 37: 83-89, 2001. (Pubitemid 32738067)
35. Anderson J, Ramsay A, Gould S and Pritchard-Jones K: PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 159: 1089-1096, 2001. (Pubitemid 32847199)
36. Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ III and Schäfer BW: Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 93: 13164-13169, 1996. (Pubitemid 26382787)
37. Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E and Rauscher FJ III: Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res 60: 5803-5814, 2000.
38. Xia SJ, Holder DD, Pawel BR, Zhang C and Barr FG: High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am J Pathol 175: 2600-2608, 2009.
39. Chen B, Athanasiou M, Gu Q and Blair DG: Drm/Gremlin transcriptionally activates p21(Cip1) via a novel mechanism and inhibits neoplastic transformation. Biochem Biophys Res Commun 295: 1135-1141, 2002.
40. Bialik S and Kimchi A: DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death. Semin Cancer Biol 14: 283-294, 2004. (Pubitemid 38824589)